Adverse events for rosuvastatin AE Proportion (%)* Myopathy 12/872 (1.38) Rhabdomyolysis 38/872 (4.36) Renal failure 44/872 (5.05) *Rosuvastatin AEs divided by the total number of all serious and nonserious AEs from 1999 to 2004 for the six statin drugs in the marketplace Bennett WM, moderator. Forum. Postgraduate Education Course. Renal Week 2005; November 8-13, 2005; Philadelphia, PA.
Renal clearance of statins Atorvastatin <2 Lovastatin 10 Simvastatin 13 Pravastatin 20 Cerivastatin 24 Rosuvastatin 28 Bennett WM, moderator. Forum. Postgraduate Education Course. Renal Week 2005; November 8-13, 2005; Philadelphia, PA.